Sethuraman Natarajan's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Nov 13, 2024
- Accession no.
- 0001689375-24-000066
- Filed
- Nov 13, 2024
- Trade date
- Nov 11-13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $82.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sethuraman NatarajanCIK 0001873394 | Officer (President, Research & Develop.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | Common Stock | SSaleDisposed | −1,409 | $20.01 | −$28,194.09 | 163,588 | Direct | |
| Nov 13, 2024 | Common Stock | SSaleDisposed | −2,700 | $20.04 | −$54,108 | 160,888 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.